“An Open-Label Extension of Two Phase 3 Studies Evaluating Long-Term Efficacy of FMX101 4% Minocycline Foam for the Treatment of Acne Vulgaris”. SKIN The Journal of Cutaneous Medicine, vol. 3, Nov. 2019, p. S1, https://doi.org/10.25251/skin.3.supp.1.